These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
136 related articles for article (PubMed ID: 31876819)
1. Prognostic Value of Baseline Total Metabolic Tumor Volume Measured on FDG PET in Patients With Richter Syndrome. Pontoizeau C; Girard A; Mesbah H; Haumont LA; Devillers A; Tempescul A; Salaün PY; Lamy T; Le Jeune F; Palard-Novello X Clin Nucl Med; 2020 Feb; 45(2):118-122. PubMed ID: 31876819 [TBL] [Abstract][Full Text] [Related]
2. Prognostic value of metabolic tumour volume on baseline Shagera QA; Cheon GJ; Koh Y; Yoo MY; Kang KW; Lee DS; Kim EE; Yoon SS; Chung JK Eur J Nucl Med Mol Imaging; 2019 Jul; 46(7):1417-1427. PubMed ID: 30941463 [TBL] [Abstract][Full Text] [Related]
3. Tumor fragmentation estimated by volume surface ratio of tumors measured on 18F-FDG PET/CT is an independent prognostic factor of diffuse large B-cell lymphoma. Decazes P; Becker S; Toledano MN; Vera P; Desbordes P; Jardin F; Tilly H; Gardin I Eur J Nucl Med Mol Imaging; 2018 Sep; 45(10):1672-1679. PubMed ID: 29705879 [TBL] [Abstract][Full Text] [Related]
4. Combination of baseline FDG PET/CT total metabolic tumour volume and gene expression profile have a robust predictive value in patients with diffuse large B-cell lymphoma. Toledano MN; Desbordes P; Banjar A; Gardin I; Vera P; Ruminy P; Jardin F; Tilly H; Becker S Eur J Nucl Med Mol Imaging; 2018 May; 45(5):680-688. PubMed ID: 29344718 [TBL] [Abstract][Full Text] [Related]
5. Pretherapy metabolic tumour volume is an independent predictor of outcome in patients with diffuse large B-cell lymphoma. Sasanelli M; Meignan M; Haioun C; Berriolo-Riedinger A; Casasnovas RO; Biggi A; Gallamini A; Siegel BA; Cashen AF; Véra P; Tilly H; Versari A; Itti E Eur J Nucl Med Mol Imaging; 2014 Nov; 41(11):2017-22. PubMed ID: 24902639 [TBL] [Abstract][Full Text] [Related]
7. Metabolic tumor burden on baseline Chen S; He K; Feng F; Wang S; Yin Y; Fu H; Wang H Eur J Nucl Med Mol Imaging; 2019 Aug; 46(9):1830-1839. PubMed ID: 31187163 [TBL] [Abstract][Full Text] [Related]
8. [Prognostic value of pretreatment (18)F-FDG PET-CT for patients with advanced diffuse large B-cell lymphoma]. Ding CY; Guo Z; Sun J; Yang WP; Li TR Zhonghua Zhong Liu Za Zhi; 2018 Jul; 40(7):528-533. PubMed ID: 30060362 [No Abstract] [Full Text] [Related]
10. Molecular Profile and FDG-PET/CT Total Metabolic Tumor Volume Improve Risk Classification at Diagnosis for Patients with Diffuse Large B-Cell Lymphoma. Cottereau AS; Lanic H; Mareschal S; Meignan M; Vera P; Tilly H; Jardin F; Becker S Clin Cancer Res; 2016 Aug; 22(15):3801-9. PubMed ID: 26936916 [TBL] [Abstract][Full Text] [Related]
11. Prognostic value of baseline metabolic tumor volume and total lesion glycolysis in patients with lymphoma: A meta-analysis. Guo B; Tan X; Ke Q; Cen H PLoS One; 2019; 14(1):e0210224. PubMed ID: 30625203 [TBL] [Abstract][Full Text] [Related]
12. Prognostic value of total lesion glycolysis of baseline 18F-fluorodeoxyglucose positron emission tomography/computed tomography in diffuse large B-cell lymphoma. Zhou M; Chen Y; Huang H; Zhou X; Liu J; Huang G Oncotarget; 2016 Dec; 7(50):83544-83553. PubMed ID: 27835875 [TBL] [Abstract][Full Text] [Related]
13. Serum level of soluble interleukin-2 receptor is positively correlated with metabolic tumor volume on Senjo H; Kanaya M; Izumiyama K; Minauchi K; Hirata K; Mori A; Saito M; Tanaka M; Iijima H; Tsukamoto E; Itoh K; Ota S; Morioka M; Hashimoto D; Teshima T; Cancer Med; 2019 Mar; 8(3):953-962. PubMed ID: 30790452 [TBL] [Abstract][Full Text] [Related]
14. Prognostic superiority of the National Comprehensive Cancer Network International Prognostic Index over pretreatment whole-body volumetric-metabolic FDG-PET/CT metrics in diffuse large B-cell lymphoma. Adams HJ; de Klerk JM; Fijnheer R; Heggelman BG; Dubois SV; Nievelstein RA; Kwee TC Eur J Haematol; 2015 Jun; 94(6):532-9. PubMed ID: 25311082 [TBL] [Abstract][Full Text] [Related]
15. Computed tomography textural analysis for the differentiation of chronic lymphocytic leukemia and diffuse large B cell lymphoma of Richter syndrome. Reinert CP; Federmann B; Hofmann J; Bösmüller H; Wirths S; Fritz J; Horger M Eur Radiol; 2019 Dec; 29(12):6911-6921. PubMed ID: 31236702 [TBL] [Abstract][Full Text] [Related]
16. Prognostic value of the metabolic bulk volume in patients with diffuse large B-cell lymphoma on baseline Delaby G; Hubaut MA; Morschhauser F; Besson A; Huglo D; Herbaux C; Baillet C Leuk Lymphoma; 2020 Jul; 61(7):1584-1591. PubMed ID: 32100597 [TBL] [Abstract][Full Text] [Related]
18. A better prediction of progression-free survival in diffuse large B-cell lymphoma by a prognostic model consisting of baseline TLG and %ΔSUV Zhang YY; Song L; Zhao MX; Hu K Cancer Med; 2019 Sep; 8(11):5137-5147. PubMed ID: 31343111 [TBL] [Abstract][Full Text] [Related]
19. FDG PET/CT Maximum Tumor Dissemination to Predict Recurrence in Patients with Diffuse Large B-Cell Lymphoma. Jo JH; Chung HW; Kim SY; Lee MH; So Y Nucl Med Mol Imaging; 2023 Feb; 57(1):26-33. PubMed ID: 36643943 [TBL] [Abstract][Full Text] [Related]
20. High total metabolic tumor volume at baseline predicts survival independent of response to therapy. Vercellino L; Cottereau AS; Casasnovas O; Tilly H; Feugier P; Chartier L; Fruchart C; Roulin L; Oberic L; Pica GM; Ribrag V; Abraham J; Simon M; Gonzalez H; Bouabdallah R; Fitoussi O; Sebban C; López-Guillermo A; Sanhes L; Morschhauser F; Trotman J; Corront B; Choufi B; Snauwaert S; Godmer P; Briere J; Salles G; Gaulard P; Meignan M; Thieblemont C Blood; 2020 Apr; 135(16):1396-1405. PubMed ID: 31978225 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]